Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma

Severe asthma affects an estimated 5–10% of the total asthma patient population [1]. Various demographic factors, such as sex, age, obesity and age of onset, have been associated with asthma disease severity [2, 3], and the efficacy of asthma treatments has previously been found to vary depending on patient demographics [4, 5]. Dupilumab treatment versus placebo improved exacerbation rate and lung function outcomes in patients with uncontrolled moderate-to-severe asthma and high type 2 biomarkers at baseline, regardless of baseline characteristics in the phase 3 QUEST study https://bit.ly/3yR7MlD

[1]  G. Canonica,et al.  Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. , 2020, The Lancet. Respiratory medicine.

[2]  G. Canonica,et al.  EAACI Biologicals Guidelines—Recommendations for severe asthma , 2020, Allergy.

[3]  G. Canonica,et al.  Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma , 2020, Allergy.

[4]  M. Wechsler,et al.  Asthma over the Adult Life Course: Gender and Hormonal Influences. , 2019, Clinics in chest medicine.

[5]  B. Modena,et al.  Asthma Biologics: Comparing Trial Designs, Patient Cohorts and Study Results. , 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[6]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[7]  K. Rabe,et al.  Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.

[8]  F. Holguin,et al.  A review of obesity and asthma across the life span , 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.

[9]  N. Graham,et al.  Commonality of the IL-4/IL-13 pathway in atopic diseases , 2017, Expert review of clinical immunology.

[10]  G. Rolla,et al.  Effects of omalizumab in severe asthmatics across ages: A real life Italian experience. , 2016, Respiratory medicine.

[11]  E. R. Sutherland,et al.  Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial , 2016, The Lancet.

[12]  L. Macdonald,et al.  Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice , 2014, Proceedings of the National Academy of Sciences.

[13]  F. Alt,et al.  Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes , 2014, Proceedings of the National Academy of Sciences.

[14]  J. Fahy.  Type 2 inflammation in asthma — present in most, absent in many , 2014, Nature Reviews Immunology.

[15]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.